Background: The regulation of the cutaneous steroidogenesis in patients with androgenetic alopecia remains largely unclear. Objective: The purpose of this study was to quantify the expression of the sex-determining genes in different scalp areas. Methods: Paired scalp specimens from frontal and occipital scalp areas of 10 patients were examined by real-time RT-PCR for mRNA expression and of 40 patients (mean age 34.9 years, range 22–58) by Western blotting for protein analysis. Results: The SOX-9 mRNA was most abundant in the skin, while SF-1 mRNA was sparsely detected. The protein levels of DAX-1, SRY and WT-1 were significantly higher in the bald scalp (p = 0.003, 0.004 and 0.03, respectively). Only the SRY expression showed a positive correlation with the baldness severity in Norwood-Hamilton classification (p = 0.024). There was no association between patient’s age and the protein levels. Immunostaining of SOX-9 was detected in the outer root sheath keratinocytes of hair follicles but not in the dermal papillae. Conclusion: Further study on a larger population, including normal subjects and female patients, is needed to confirm the pathogenic role of sex-determining genes in androgenetic alopecia.

Keywords:
Androgen, Androgenetic alopecia, Hair follicle, Sex determination
1.
Hoffmann R: Steroidogenic isoenzymes in human hair and their potential role in androgenetic alopecia. Dermatology 2003;206:85–95.
2.
Andersson S: Steroidogenic enzymes in skin. Eur J Dermatol2001;11:293–295.
3.
Price VH: Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003;8:24–27.
4.
Chen W, Zouboulis CC, Fritsch M, Blume-Peytavi U, Kodelja V, Goerdt S, Luu-The V, Orfanos CE: Evidence of heterogeneity and quantitative differences of the type 1 5α-reductase expression in cultured human skin cells – evidence of its presence in melanocytes. J Invest Dermatol 1998;110:84–89.
5.
Ellis JA, Stebbing M, Harrap SB: Genetic analysis of male pattern baldness and the 5α-reductase genes. J Invest Dermatol 1998;110:849–853.
6.
Sreekumar GP, Pardinas J, Wong CQ, Whiting D, Katz HI, Price V, Zlotogorski A, Roberts J, Clark BC, Stenn K, Parimoo S: Serum androgens and genetic linkage analysis in early onset androgenetic alopecia. J Invest Dermatol 1999;113:277–279.
7.
Chumlea WC, Rhodes T, Girman CJ, Johnson-Levonas A, Lilly FR, Wu R, Guo SS: Family history and risk of hair loss. Dermatology 2004;209:33–39.
8.
Vilain E, McCabe ER: Mammalian sex determination: from gonads to brain. Mol Genet Metab 1998;65:74–84.
9.
Bowles J, Koopman P: New clues to the puzzle of mammalian sex determination. Genome Biol 2001;2:1025.
10.
Patel MV, McKay IA, Burrin JM: Transcriptional regulators of steroidogenesis, DAX-1 and SF-1, are expressed in human skin. J Invest Dermatol 2001;117:1559–1565.
11.
Sugawara T, Saito M, Fujimoto S: Sp1 and SF-1 interact and cooperate in the regulation of human steroidogenic acute regulatory protein gene expression. Endocrinology 2000;141:2895–2903.
12.
Lalli E, Melner MH, Stocco DM, Sassone-Corsi P: DAX-1 blocks steroid production at multiple levels. Endocrinology 1998;139:4237–4243.
13.
Tremblay JJ, Viger RS: Nuclear receptor Dax-1 represses the transcriptional cooperation between GATA-4 and SF-1 in Sertoli cells. Biol Reprod 2001;64:1191–1199.
14.
Holter E, Kotaja N, Makela S, Strauss L, Kietz S, Janne OA, Gustafsson JA, Palvimo JJ: Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1. Mol Endocrinol 2002;16:515–528.
15.
Zaia A, Fraizer GC, Piantanelli L, Saunders GF: Transcriptional regulation of the androgen signaling pathway by the Wilms’ tumor suppressor gene WT1. Anticancer Res 2001;21:1–10.
16.
Clarkson MJ, Harley VR: Sex with two SOX on: SRY and SOX9 in testis development. Trends Endocrinol Metab 2002;13:106–111.
17.
Koopman P, Bullejos M, Bowles J: Regulation of male sexual development by Sry and Sox9. J Exp Zool 2001;290:463–474.
18.
Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, Scherbaum WA, Orfanos CE, McCann SM, Bornstein SR: Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA 2002;99:7148–7153.
19.
Sun HS, Hsiao KY, Hsu CC, Wu MH, Tsai SJ: Transactivation of steroidogenic acute regulatory protein in human endometriotic stromal cells is mediated by the prostaglandin EP2 receptor. Endocrinology 2003;144:3934–3942.
20.
Chen W, Yang CC, Liao CY, Tsai SJ, Chen KF, Hung CL, Sheu HM, Zouboulis CC: Expression of sex-determining genes in human sebaceous glands and their possible roles in pathogenesis of acne. J Eur Acad Dermatol Venereol 2006;20:846–852.
21.
Thiboutot D, Jabara S, McAllister JM, Sivarajah A, Gilliland K, Cong Z, Clawson G: Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 2003;120:905–914.
22.
Zhao L, Bakke M, Hanley NA, Majdic G, Stallings NR, Jeyasuria P, Parker KL: Tissue-specific knockouts of steroidogenic factor 1. Mol Cell Endocrinol2004;215:89–94.
23.
Guarrera M, Rebora A: Kenogen in female androgenetic alopecia: a longitudinal study. Dermatology 2005;210:18–20.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.